

- Elliott M., Kim J., Dou A., Antrás F., Amir E., Nadler M., Van De Laar E., Yu C., Cheikh R., Silvestro A., Siu L., Bedard P., Berman H., and Cescon D., 2025, Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer, *ESMO Open*, 10(6): 105286.
<https://doi.org/10.1016/j.esmoop.2025.105286>
- Emiloju O., Storandt M., Zemla T., Tran N., Jethwa K., Mahipal A., Mitchell J., Thiels C., Mathis K., McWilliams R., Hubbard J., Sinicrope F., Shi Q., and Jin Z., 2024, Tumor-informed circulating tumor DNA for minimal residual disease detection in the management of colorectal cancer, *JCO Precision Oncology*, 8: e2300127.
<https://doi.org/10.1200/PO.23.00127>
- Faulkner L.G., Howells L.M., Pepper C., Shaw J.A., and Thomas A.L., 2022, The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis, *British Journal of Cancer*, 128(2): 297-309.
<https://doi.org/10.1038/s41416-022-02017-9>
- Hoang T., Choi M., Oh J., and Kim J., 2025, Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: a systematic review and network meta-analysis, *International Journal of Cancer*, 157(4): 722-740.
<https://doi.org/10.1002/ijc.35442>
- Isbell J., Goldstein J., Hamilton E., Liu S., Eichholz J., Buonocore D., Rusch V., Bott M., Molena D., Rocco G., Yang S., Rudin C., Jones D., Roff A., Schultz A., Chabon J., Kurtz D., Alizadeh A., Li B., and Diehn M., 2024, Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC), *Journal of Clinical Oncology*, 42(16_suppl): 8078.
https://doi.org/10.1200/JCO.2024.42.16_suppl.8078
- Kasi P.M., Fehring G., Taniguchi H., Starling N., Nakamura Y., Kotani D., Powles T., Li B.T., Pusztai L., Aushev V., Kalashnikova E., Sharma S., Malhotra M., Demko Z.P., Aleshin A., Rodriguez A., Cunningham D., Yoshino T., and Kopetz S., 2022, Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors, *JCO Precision Oncology*, 6: e2100181.
<https://doi.org/10.1200/PO.21.00181>
- Kobayashi S., Nakamura Y., Hashimoto T., Bando H., Oki E., Karasaki T., Horinouchi H., Ozaki Y., Iwata H., Kato T., Miyake H., Ohba A., Ikeda M., Chiyoda T., Hasegawa K., Fujisawa T., Matsuura K., Namikawa K., Yajima S., Yoshino T., and Hasegawa K., 2025, Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing, *International Journal of Clinical Oncology*, 30(4): 605-654.
<https://doi.org/10.1007/s10147-024-02683-0>
- Maddalena G., Pellatt A.J., Eluri M., Parseghian C.M., Aziz K., Alfaro K., Kell R., Bent A., Huey R., Uppal A., Konishi T., Overman M., Morelli M., Willis J., Shen J., Raghav K., Newhook T., Morris V., Dasari A., and Kopetz S., 2024, INTERCEPT program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): results from a prospective clinical cohort, *Journal of Clinical Oncology*, 42(3_suppl): 27.
https://doi.org/10.1200/JCO.2024.42.3_suppl.27
- Nakamura Y., Watanabe J., Akazawa N., Hirata K., Kataoka K., Yokota M., Kato K., Kotaka M., Kagawa Y., Yeh K., Mishima S., Yukami H., Ando K., Miyo M., Misumi T., Yamazaki K., Ebi H., Okita K., Miyo M., Misumi T., Yamazaki K., Ebi H., Okita K., Hamabe A., Hiroki Sokuoka H., Kobayashi S., Laliotis G., Aushev V.N., Sharma S., Jurdi A., Liu M.C., Aleshin A., Rabinowitz M., Bando H., Taniguchi H., Takemasa I., Kato T., Kotani D., Mori M., Yoshino T., and Oki E., 2024, ctDNA-based molecular residual disease and survival in resectable colorectal cancer, *Nature Medicine*, 30: 3272-3283.
<https://doi.org/10.1038/s41591-024-03254-6>
- Negro S., Pulvirenti A., Trento C., Indraccolo S., Ferrari S., Scarpa M., Urso E., Bergamo F., Pucciarelli S., Deidda S., Restivo A., Lonardi S., and Spolverato G., 2025, Circulating tumor DNA as a real-time biomarker for minimal residual disease and recurrence prediction in stage II colorectal cancer: a systematic review and meta-analysis, *International Journal of Molecular Sciences*, 26: 2486.
<https://doi.org/10.3390/ijms26062486>
- Pantel K., and Alix-Panabières C., 2024, Minimal residual disease as a target for liquid biopsy in patients with solid tumours, *Nature Reviews Clinical Oncology*, 22(1): 65-77.
<https://doi.org/10.1038/s41571-024-00967-y>
- Pellini B., and Chaudhuri A.A., 2022, Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent, *Journal of Clinical Oncology*, 40(6): 567-575.
<https://doi.org/10.1200/JCO.21.01929>
- Quinn K., Wilfert A., Lakshmin R., Chen S., Lee A., Zhao J., Gaile D., Chang Y., McCole R., Burke J., Dustin D., Rich T., Tung J., Price K., and Chudova D., 2025, Abstract 692: Analytical validation of a tissue-free epigenomic assay for circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in early-stage cancer, *Cancer Research*, 85(8_Supplement_1): 692.
<https://doi.org/10.1158/1538-7445.am2025-692>
- Sabit H., Attia M., Mohamed N., Taha P., Ahmed N., Osama S., and Abdel-Ghany S., 2025, Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment, *Discover Oncology*, 16(1): 271.
<https://doi.org/10.1007/s12672-025-01940-6>
- Sato Y., 2025, Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges, *Exploration of Medicine*, 6: 1001349.
<https://doi.org/10.37349/emed.2025.1001349>
- Semenkovich N.P., Szymanski J.J., Earland N., Chauhan P., Pellini B., and Chaudhuri A., 2023, Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA, *Journal for Immunotherapy of Cancer*, 11(6): e006284.
<https://doi.org/10.1136/jitc-2022-006284>